Novo Nordisk A/s

This study tests if a new medicine called NNC0487-0111 is safe and helps people with obesity lose weight. About 600 adults will receive either the drug or a placebo as a weekly injection under the skin. The main goal is to see how much body weight they lose over time.

This study tests a new medicine called CagriSema to help people with overweight or obesity lose weight. About 1,400 adults will receive either CagriSema or a placebo using one of two injection devices. The study lasts about one year and measures weight change and side effects.

This study tests a weekly injection called CagriSema (cagrilintide plus semaglutide) in 80 children and teens with type 2 diabetes. The goal is to see if it safely lowers blood sugar and body weight. The trial has two parts: first, some get the drug and some get a placebo; then e…

This study will follow 600 adults with type 2 diabetes who are starting Rybelsus (a daily pill) as part of their normal treatment. The goal is to track any side effects and how well the medicine controls blood sugar over about 26 weeks. Participants take the drug as their doctor …

This study tests a new once-weekly injection (NNC0487-0111) in 400 adults with overweight or obesity and knee osteoarthritis. Participants are randomly assigned to receive either the study drug or a placebo. The goal is to see if the drug helps with weight loss and reduces knee p…